Brought to you by**:
**Sponsored. Clicking on ad links may share your email with Mercury for remarketing purposes.
Top stories today:
- 2nd Alzheimer’s drug approved by FDA: donanemab (Kisunla) by Lilly
- Figma disables Make Design feature after it was found copying Apple
- Runway AI in talks to raise $450M at $4B valuation
- Tesla stock +10% after deliveries fall less than expected
- Exits for Europe’s VC-backed fintechs continue to decelerate
0. Data and calendar
All values as of 6 AM ET / 3 AM PT, other than S&P500 and NASDAQ close (4 PM ET / 1 PM PT).
All times are ET.
1. 2nd Alzheimer’s drug approved by FDA: donanemab (Kisunla) by Eli Lilly
22%-36% slowdown of clinical decline was observed in donanemab’s Phase 3 clinical trial:
$13K for a 6-month course, $32K for 12 months, and $49K for 18 months.
Similar efficacy and pricing vs. lecanemab, the 1st approved Alzheimer’s drug from Eisai.
Donanemab requires shots every month, rather than every 2 weeks.
Lilly stock -1%.
Alzheimer’s drug market expected at $13B/year by 2030, from $0.25B in 2024.
2. Figma disables Make Design feature after it was found copying Apple’s designs
Figma says that they did not train their own models.
OpenAI’s GPT-4o and Amazon’s Titan Image Generator G1 are used instead.
“Soon”: when Make Designs will be re-enabled.
After five years of creating a powerful banking* experience loved by over 200K startups, Mercury is building upon that bank account with new products that power critical financial workflows.
Pay your bills more accurately with software that eliminates manual work — built right into your Mercury account.
Why send money to another platform to pay your bills? By eliminating third-party processing, you pay bills the moment you need to, allowing you to maximize your cash flow.
**Sponsored. Clicking on ad links may share your email with Mercury for remarketing purposes.
4. Runway AI in talks to raise $450M at $4B valuation
It would make the text-to-video AI firm the #10 most valuable generative AI startup:
